In the hunt for a $100M IPO, Biohaven polishes up discards from Bristol-Myers, AstraZeneca
When Biohaven Pharmaceutical spun out of Yale a few years ago, company executives talked a lot about their focus on depression and anxiety — tough targets in R&D by any account. But on Friday the stealthy Biohaven jumped out with a $100 million IPO filing, after undergoing a radical, low-key revamp of its pipeline focus, clearly aimed at offering investors a chance at a late-stage biotech eyeing near-term FDA applications.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.